Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Comparative Study1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Clin Allergy1
Search Results
Sort by
- BookNikolaos Labrou, editor.Summary: This edited work presents studies that clarify several aspects of the development and application of therapeutic enzymes. Therapeutic enzymes exhibit fascinating features and opportunities, and represent a significant and promising subcategory of modern biopharmaceuticals for the treatment of several severe diseases. Research and drug developments efforts and the advancements in biotechnology over the past twenty years have greatly assisted the introduction of efficient and safe enzyme-based therapies for a range of both rare and common disorders. The introduction and regulatory approval of twenty different recombinant enzymes has enabled effective enzyme-replacement therapy. This book covers mainly three areas of recombinant therapeutic enzymes and their clinical and pharmaceutical technology: (i) overview of the production process and biochemical characterization of therapeutic enzymes, (ii) focuses upon the engineering strategies and delivery methods of therapeutic enzymes, (iii) clinical applications of selected therapeutic enzymes, including aspects on their mechanisms of action and information on safety, immunogenicity issues and various adverse events of the enzymes used for therapy. The topic of this book is particularly relevant to academics, researchers and students undertaking advanced undergraduate/postgraduate programs in the biopharmaceutical/biotechnology area who wish to gain a comprehensive understanding of enzyme-based therapeutic molecules.
Contents:
Chapter 1. Introduction to therapeutic enzymes
Chapter 2. Upstream processing technologies
Chapter 3. Downstream processing technologies
Chapter 4. Enzyme Manufacturing Process and Quality Control Evaluations
Chapter 5. Regulatory guidance in the production of therapeutic enzymes
Chapter 6. Biophysical methods for the characterization of Enzyme Therapeutics Bertrand Raynal Patrick England
Chapter 7. Clinical Development of a therapeutic enzyme
Chapter 8. Chemical modifications of therapeutic proteins
Chapter 9. Formulation of therapeutic enzymes
Chapter 10. Engineering of therapeutic enzymes for improving activity
Chapter 11. Engineering of therapeutic enzymes for improving stability
Chapter 12. Design and engineering of deimmunized therapeutic enzymes
Chapter 13. Nanoparticles for delivery of therapeutic enzymes
Chapter 14. Targeted delivery of therapeutic enzymes
Chapter 15. Oral and inhalable enzyme therapies
Chapter 16. Regulatory issues
Chapter 17. Enzyme replacement therapies
Chapter 18. Pharmacodynamics and pharmacokinetics issues of enzyme replacement therapy
Chapter 19. Enzyme therapy for lysosomal storage disorders
Chapter 20. Enzyme therapy for myocardial infarction
Chapter 21. Enzyme therapy for chronic gout
Chapter 22. Enzyme therapy for tumor lysis syndrome
Chapter 23. Enzyme therapy for collagen-based disorders
Chapter 24. Enzyme therapy for severe combined immunodeficiency disease
Chapter 25. Enzyme therapy for detoxification of methotrexate
Chapter 26. Enzyme therapy vitreomacular adhesion
Chapter 27. L-Asparaginase as anticancer agent
Chapter 28. Pancreatic enzyme replacement therapy
Chapter 29. Enzymes in metabolic anticancer therapy
Chapter 30. L-Arginase for L-Arg depletion therapy in cancer
Chapter 31. Methionine L-lyase for L-Met depletion therapy in cancer
Chapter 32. Enzyme therapy for celiac sprue
Chapter 33. Acid ceramidase
Chapter 34. Lysoso mal acid lipase
Chapter 35. Alkaline phosphatase and hypophosphatasia
Chapter 36. Enzybiotics: Antibiotic enzymes as drugs and therapeutics
Chapter 37. Anti-inflammatory enzymes
Chapter 38. Phenylalanine ammonia lyase for the treatment of phenylketonuria
Chapter 39. Clinical applications of Hyaluronidase
Chapter 40. Superoxide dismutase and oxidative stress modulation
Chapter 41. Organophosphate hydrolases as catalytic bioscavengers
Chapter 42. Novel therapeutic proteases
Chapter 43. Genome-editing enzymes
Chapter 44. Gene therapy for enzyme deficiency: current status and future prospects.Digital Access Springer 2019 - ArticleKurimoto Y, Baba S.Clin Allergy. 1978 Mar;8(2):175-85.198 asthmatics and twenty healthy persons were studied by RAST and in vivo tests with four common inhalant allergens. (a) Higher RAST classes were elicited with mite (Dermatophagoides farinae) extract and lower classes with other allergens. The agreement between positive RAST and skin or P-K tests was highest with the mite extract. RAST sensitivity was dependent on the kinds of allergens and was most sensitive to mite extract. Positive RAST was most closely related to the prick test reactions. (b) RASTs to house dust and mite extract were examined in terms of the threshold dosage of house dust and also the types of bronchial response (early, dual and late) induced by a certain amount of house dust; higher RAST classes were found in subjects with bronchial response to the dual or early type, elicited by a threshold dosage of diluted extract, while lower RAST classes were found in cases of the late-type response elicited by the threshold dosage of concentrated extract. (c) Changes in IgE antibodies to house dust and mite extract were estimated in patients with positive house dust provocation. A greater increase occurred in cases of dual or early response, a smaller increase in those with a late response. Despite discordances in skin tests and RAST between house dust and mite extracts, the increases in IgE antibodies to mite extracts as well as house dust were observed in all cases, presumably caused by an allergenic identity between the allergens.